Behind-The-Counter Class Requires Investment, With Payoff Unclear– GAO
This article was originally published in The Tan Sheet
Executive Summary
A behind-the-counter drug class in the U.S. is not feasible unless the government addresses some significant logistical challenges, the Government Accountability Office says
You may also be interested in...
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
The questions FDA poses for a March 22-23 hearing indicate the agency is delving into greater detail than in its previous discussions of alternative routes to access pharmaceutical treatments. FDA says decisions would be made case by case, but refers to treating conditions including high cholesterol, high blood pressure, migraines and asthma.
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
The questions FDA poses for a March 22-23 hearing indicate the agency is delving into greater detail than in its previous discussions of alternative routes to access pharmaceutical treatments. FDA says decisions would be made case by case, but refers to treating conditions including high cholesterol, high blood pressure, migraines and asthma.
FDA Considers “New Paradigm” To Facilitate Third Class Of Drugs
Approach that “under conditions of safe use” would allow nonprescription access to some categories of Rx drugs for treating chronic conditions is among topics for FDA hearing on switching Rx products to behind-the-counter status or other alternative routes.